---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001980"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:50:16.595695+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma highlights YUPELRI growth, $250M buyback progress, and ampreloxetine Phase 3 start

## Summary
- YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.
- $250M capital return program ~50% completed as of 12/31/2022; ~$95M GSK buyback and ~$33M open market repurchases.
- Ampreloxetine Phase 3 CYPRESS trial in MSA patients with nOH to start Q1 2023; orphan drug submission planned.
- Targeting Non-GAAP profitability by 2H 2023; $50M milestone if TRELEGY sales reach ~$2.86B in 2023.
- Sale of TRELEGY royalty interests for $1.1B upfront eliminated all debt; financial restructuring completed.

## SEC filing metadata
- accession: 0001104659-23-001980
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/0001104659-23-001980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/tm232391d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001980
- JSON: https://secwatch.observer/filing/0001104659-23-001980.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.